Jade Biosciences Inc stock is traded at $14.10, with a volume of 1,288,785. It is down -6.25% in the last 24 hours and up +0.21% over the past month. Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Previous Close:
$15.04
Open:
$15.02
24h Volume:
1,288,785
Relative Volume:
1.50
Market Cap:
$896.72M
Revenue:
-
Net Income/Loss:
-$129.61M
P/E Ratio:
-
EPS:
-$2.99
Net Cash Flow:
-$116.59M
1W Performance:
-0.98%
1M Performance:
+0.21%
6M Performance:
-44.18%
1Y Performance:
+46.88%
1-Day Range:
$14.06$15.03
1-Week Range:
$13.55$15.19
52-Week Range:
$8.36$28.00
Jade Biosciences Inc Stock (JBIO) Company Profile
Name
Jade Biosciences IncSector
HealthcareIndustry
BiotechnologyPhone
(781) 312-3013Address
221 CRESCENT ST., WALTHAM, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS